Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

  • In development
  • GID-TA11545
  • Expected publication date: 

Documents

Documents created during the development process.

Draft guidance

Declaration of interests

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators